October 10, 2025 a 01:00 pm
ZBH: Analysts Ratings - Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. has a significant presence in the orthopedic reconstructive products market, serving a diverse range of medical professionals. Over the past months, analyst ratings have shown a trend towards caution, with an increase in Hold recommendations. This reflects a stable yet cautious sentiment amid economic uncertainties.
Historical Stock Grades
As of October 2025, the sentiment surrounding Zimmer Biomet Holdings (ZBH) reflects a balanced view among analysts. The distribution of ratings suggests a cautious approach, with a predominant number of Hold recommendations indicating a hesitancy to commit strongly in either direction.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 6 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 1 |
Sentiment Development
The sentiment over the months has shown a gradual shift. While there has been a consistent pattern of strong and buy recommendations in the earlier months, recent data indicate an increasing tendency towards Hold recommendations.
- The number of Hold recommendations has seen a steady increase from 17 to 18 over recent months.
- A noticeable decrease in the Strong Buy category from 9 to 5 signals a more cautious approach by the analysts.
- Overall, analyst sentiment is stabilizing around a more neutral or wait-and-see approach.
Percentage Trends
An analysis of the ratings distribution highlights a noteworthy shift in sentiment. The decrease in percentage of Strong Buy recommendations and relative increase in Hold reflects changing market conditions and analyst expectations.
- Currently, 46% of analysts rate ZBH as Hold, up from 30% earlier this year.
- Strong Buy ratings have dropped from 40% to 15%, showing reduced bullish sentiment.
- The Buy recommendation holds steady at approximately 18%, suggesting a balanced outlook.
Latest Analyst Recommendations
Recent analyst updates show a steady trend with no significant shifts in recommendations, suggesting a consistent yet cautious outlook.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-07 | In Line | In Line | Evercore ISI Group |
| 2025-09-19 | Buy | Buy | Stifel |
| 2025-08-08 | Outperform | Outperform | RBC Capital |
| 2025-08-08 | Outperform | Outperform | Raymond James |
| 2025-08-08 | Sell | Sell | UBS |
Analyst Recommendations with Change of Opinion
Analyst recommendations with a change in opinion provide insights into shifting market expectations. There have been several significant upgrades and downgrades over the past months.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2024-12-17 | Overweight | Neutral | JP Morgan |
| 2024-07-01 | Neutral | Overweight | Piper Sandler |
| 2024-05-21 | Buy | Hold | Argus Research |
| 2024-01-04 | In Line | Outperform | Evercore ISI Group |
| 2023-08-28 | Buy | Neutral | BTIG |
Interpretation
The current assessment of Zimmer Biomet Holdings, Inc. suggests a cautious optimism among analysts. While the prevalence of Hold ratings indicates some market uncertainty, the overall stability of ratings over time suggests a level of trust in the company’s long-term prospects. The lack of major downgrades or upgrades reflects a wait-and-see approach as market conditions evolve.
Conclusion
Zimmer Biomet Holdings, Inc. presents a balanced risk-reward profile as per the latest analyst sentiment. While there is a clear trend towards more neutral recommendations, suggesting a degree of caution, the absence of aggressive downgrades is reassuring. Analysts appear to be adopting a conservative stance amidst potential market volatility. This emphasizes the need for potential investors to closely monitor market conditions and company developments while considering their investment strategy in ZBH.